Trial Profile

Durvalumab+ Anlotinib + Standard Chemotherapy in First-line Treatment of Extensive Small-cell Lung Cancer: a Single-arm Phase II Clinical Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Durvalumab (Primary) ; Carboplatin; Cisplatin; Etoposide
Indications Brain metastases; Liver metastases; Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

08 Apr 2026 Status changed from recruiting to completed.
04 Jun 2024 Efficacy and safety results (n=22) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
10 Apr 2022 Planned End Date changed from 4 Nov 2022 to 20 Nov 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com